Development

Pipeline

AP-89 is Alita's first pipeline product, targeting an initial indication of reducing the frequency of urinary tract infection in patients with a history of uncomplicated recurrent urinary tract infections. Alita has the exclusive U.S. rights to develop and commercialize AP-89, and will be leading and funding all clinical, regulatory, and marketing and sales initiatives in this country. Alita owns the IND and will own the BLA upon submission. An earlier generation of the product is marketed by OM PHARMA in over 40 countries.